Noida, India

Lalit Kumar

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Jubilant Generics Limited. Active years: 2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lalit Kumar. Retrieved from https://idiyas.com/inventor/lalit-kumar-xxrh8pk2

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0


Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lalit Kumar - Innovator in Pharmaceutical Processes.

Introduction

Lalit Kumar is a notable inventor based in Noida, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of processes for drug preparation. His work is characterized by innovation and a commitment to improving existing methodologies.

Latest Patents

Lalit Kumar holds a patent for a process for the preparation of apixaban and intermediates thereof. This invention relates to an improved method for synthesizing apixaban, a medication used to prevent blood clots. The patent also includes novel intermediates of Formula V and their preparation processes.

Career Highlights

Lalit Kumar is currently employed at Jubilant Generics Limited, where he applies his expertise in pharmaceutical development. His role involves collaborating with a team of professionals to enhance drug formulation processes. His contributions have been instrumental in advancing the company's research initiatives.

Collaborations

Some of his coworkers include Rakesh Tiwari and Amit Srivastava. Together, they work on various projects aimed at improving pharmaceutical processes and developing new drug formulations.

Conclusion

Lalit Kumar's innovative work in the pharmaceutical industry exemplifies the impact of dedicated inventors on healthcare advancements. His patent for the preparation of apixaban showcases his commitment to improving drug synthesis methods.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…